Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Distinct Factors Influence on Complete Hematological Response Maintenance in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b: From a Phase 2 Study in South Korea

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Yunsuk Choi, June-won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2024) 144 (Supplement 1): 6673.

https://doi.org/10.1182/blood-2024-206881

Published: 2024

Journal Articles

Refining Symptom Response Criteria in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2024) 144 (Supplement 1): 6642.

https://doi.org/10.1182/blood-2024-206509

Published: 2024

Journal Articles

Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon

Seug Yun Yoon, Jong-Ho Won, Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Yunsuk Choi, June-won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2024) 144 (Supplement 1): 3170.

https://doi.org/10.1182/blood-2024-207042

Published: 2024

Journal Articles

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit: Results from 12-Month Core Study

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-Won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2023) 142 (Supplement 1): 4575.

https://doi.org/10.1182/blood-2023-184431

Published: 2023

Journal Articles

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Sung-Eun Lee, MD PhD, Joon Seong Park, MD, Young Rok Do, PhDMD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MDPhD, Sukjoong Oh, MDPhD, Jae-Yong Kwak, Jeong-A Kim, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Dong-Wook Kim, MD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-139253

Published: 2020

Journal Articles

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Sung-Eun Lee, MD, Joon Seong Park, MD, Hyeoung-Joon Kim, MD PhD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MD PhD, Sukjoong Oh, MD PhD, Young Rok Do, PhDMD, Yunsuk Choi, MD, Jae-Yong Kwak, MD PhD, Jeong-A Kim, MD PhD, Kyoo Hyung Lee, MD PhD, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Jinny Park, MD PhD, Jihyun Kwon, MD, Dong-Wook Kim

Blood (2019) 134 (Supplement_1): 1643.

https://doi.org/10.1182/blood-2019-126376

Published: 2019

Journal Articles

Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study

Dae Young Zang, MD PhD, Won Sik Lee, MD PhD, Yeung-Chul Mun, Young Rok Do, PhD MD, Sukjoong Oh, MD PhD, Sung-Eun Lee, MD PhD, Soo Young Choi, Dong-Wook Kim, MD PhD

Blood (2018) 132 (Supplement 1): 4252.

https://doi.org/10.1182/blood-2018-99-118026

Published: 2018

Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Blood (2018) 132 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2018-99-110568

Published: 2018

Journal Articles

Prognostic Implication of Early Molecular Response at 3 Months in Chronic Myeloid Leukemia Patients: A Comparison of Imatinib and Second Generation Tyrosine Kinase Inhibitors

Dong-Wook Kim, MD PhD, Sung-Eun Lee, MD PhD, Soo Young Choi, Dae Young Zang, MD PhD, Won-Sik Lee, Yeung-Chul Mun, Young Rok Do, PhD MD, Sukjoong Oh, MD PhD

Blood (2018) 132 (Supplement 1): 3017.

https://doi.org/10.1182/blood-2018-99-117631

Published: 2018

Journal Articles

High Incidence of Hepatitis B Viral Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Jieun Uhm, MD PhD, Sung-Hyun Kim, MD PhD, Sukjoong Oh, MD PhD, Dae Young Zang, MD PhD, Young Rok Do, PhD MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Sung-Eun Lee, MD PhD, Dong-Wook Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3010.

https://doi.org/10.1182/blood-2018-99-117543

Published: 2018

Journal Articles

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Blood (2017) 130 (Supplement 1): 317.

https://doi.org/10.1182/blood.V130.Suppl_1.317.317

Published: 2017

Journal Articles

Characterization of ABL Compound Mutation Using Sanger and Subcloning Sequencing in Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia

Sukjoong Oh, Ki Hoon Kang, Won-Sik Lee, MD PhD, Hyeoung-Joon Kim, Jee Hyun Kong, Yunsuk Choi, MD, Young Rok Do, MD PhD, Jae-Yong Kwak, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, MD PhD, Yeung-Chul Mun, MD PhD, Young-Woong Won, Sung-Eun Lee, MD, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 2864.

https://doi.org/10.1182/blood.V130.Suppl_1.2864.2864

Published: 2017

Journal Articles

The Impact of Early Molecular Response at 3 Months on Long-Term Survival Was Enhanced in the CP CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors

Sung-Eun Lee, MD, Won-Sik Lee, MD PhD, Hyeoung-Joon Kim, Jee Hyun Kong, Yunsuk Choi, MD, Young Rok Do, MD PhD, Jae-Yong Kwak, Sukjoong Oh, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, Yeung-Chul Mun, MD PhD, Young-Woong Won, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 2873.

https://doi.org/10.1182/blood.V130.Suppl_1.2873.2873

Published: 2017

Journal Articles

Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Won-Sik Lee, MD PhD, Hye-Young Song, Hyeoung-Joon Kim, Jee Hyun Kong, Young Rok Do, MD PhD, Jae-Yong Kwak, Sukjoong Oh, Sung-Hyun Kim, MD PhD, Jeong-A Kim, Dae Young Zang, MD PhD, Yeung-Chul Mun, MD PhD, Young-Woong Won, Sung-Eun Lee, MD, Yunsuk Choi, MD, Dong-Wook Kim, MD PhD

Blood (2017) 130 (Supplement 1): 1593.

https://doi.org/10.1182/blood.V130.Suppl_1.1593.1593

Published: 2017

Journal Articles

Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial

Blood (2015) 126 (23): 476.

https://doi.org/10.1182/blood.V126.23.476.476

Published: 2015

Journal Articles

Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib

Blood (2015) 126 (23): 4053.

https://doi.org/10.1182/blood.V126.23.4053.4053

Published: 2015

Journal Articles

Results from the Korean Imatinib Discontinuation Study (KIDS): Updated Data with 15-Month Median Follow up

Blood (2014) 124 (21): 3155.

https://doi.org/10.1182/blood.V124.21.3155.3155

Published: 2014

Journal Articles

Achieving Complete Cytogenetic Response and BCR-ABL PCR IS <1% within 12 Moths Are Important Goals for Imatinib Therapy in Newly Diagnosed, TKI-Naive Chronic Myeloid Leukemia Accelated Phase Patients

Hawk Kim, Eun-Jung Jang, Sung-Eun Lee, Won Sik Lee, MD PhD, Sukjoong Oh, MD PhD, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 3158.

https://doi.org/10.1182/blood.V124.21.3158.3158

Published: 2014

Journal Articles

Results From The Korean Imatinib Discontinuation Study (KIDS): Updated Data With 14-Month Median Follow Up

Blood (2013) 122 (21): 4003.

https://doi.org/10.1182/blood.V122.21.4003.4003

Published: 2013

Journal Articles

Restrospective Multicenter Study Evaluating Efficacy and Safety of Dasatinib and Nilotinib in Patients with Imatinib-Resistant or –intolerant Chronic Myeloid Leukemia in Chronic Phase: Korean CML Working Party

Blood (2012) 120 (21): 1691.

https://doi.org/10.1182/blood.V120.21.1691.1691

Published: 2012

NARROW

Distinct Factors Influence on Complete Hematological Response Maintenance in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b: From a Phase 2 Study in South Korea

Refining Symptom Response Criteria in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b

Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit: Results from 12-Month Core Study

Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Long-Term Follow-up after Treatment Discontinuation in Patients with Chronic Myeloid Leukemia: The Korean Imatinib Discontinuation (KID) Study

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Prognostic Implication of Early Molecular Response at 3 Months in Chronic Myeloid Leukemia Patients: A Comparison of Imatinib and Second Generation Tyrosine Kinase Inhibitors

High Incidence of Hepatitis B Viral Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Deeper Molecular Response in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 36 Months Follow-up

Characterization of ABL Compound Mutation Using Sanger and Subcloning Sequencing in Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia

The Impact of Early Molecular Response at 3 Months on Long-Term Survival Was Enhanced in the CP CML Patients Treated with Second-Generation Tyrosine Kinase Inhibitors

Very Early Molecular Response at 1 Month Is a Predictor of the Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial

Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib

Results from the Korean Imatinib Discontinuation Study (KIDS): Updated Data with 15-Month Median Follow up

Achieving Complete Cytogenetic Response and BCR-ABL PCR IS <1% within 12 Moths Are Important Goals for Imatinib Therapy in Newly Diagnosed, TKI-Naive Chronic Myeloid Leukemia Accelated Phase Patients

Results From The Korean Imatinib Discontinuation Study (KIDS): Updated Data With 14-Month Median Follow Up

Restrospective Multicenter Study Evaluating Efficacy and Safety of Dasatinib and Nilotinib in Patients with Imatinib-Resistant or –intolerant Chronic Myeloid Leukemia in Chronic Phase: Korean CML Working Party

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only